Roche's Phase 3 Data Show Lymphoma Treatment Can Reduce Disease Risks
December 12 2022 - 2:26AM
Dow Jones News
By Mauro Orru
Roche Holding AG presented new data from a Phase 3 study showing
that its Polivy antibody-drug can significantly reduce the risk of
disease deterioration or death for people with untreated diffuse
large B-cell lymphoma.
The Swiss pharmaceutical company said Monday that most patients
with the untreated disease that received Polivy in combination with
rituximab, cyclophosphamide, doxorubicin and prednisone, or
rituximab, cyclophosphamide, doxorubicin, vincristine and
prednisone, reported clinically meaningful improvements in lymphoma
symptoms after the first cycle of treatment.
"These updated Polarix data indicate the potential benefits that
this Polivy based-regimen could bring to people living with this
aggressive type of lymphoma, and demonstrate our commitment to
developing new treatment options," said Levi Garraway, Roche's
Chief Medical Officer and Head of Global Product Development.
Polivy is currently marketed in the European Union for the
treatment of relapsed or refractory diffuse large B-cell lymphoma,
the most common form of non-Hodgkin lymphoma.
Separately, Roche on Sunday unveiled new data from a Phase 3
study in China showing that the crovalimab antibody is
well-tolerated in people with paroxysmal nocturnal haemoglobinuria,
an ultra-rare and life-threatening blood condition. The study met
its primary efficacy endpoints of transfusion avoidance and
haemolysis control.
The company also presented interim Phase 3 data showing that
Hemlibra achieved meaningful bleed control with a favorable safety
profile in infants of up to 12 months with severe haemophilia A, an
inherited, serious disorder in which blood doesn't clot
properly.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
December 12, 2022 02:11 ET (07:11 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2023 to Jul 2024